Ruxolitinib for Glucocorticoid | 合法藥品大搜索

由 R Zeiser 著作 · 2020 · 被引用 123 次 — Ruxolitinib is an oral selective inhibitor of JAK1 and JAK2 that reduces the incidence and severity of GVHD in vivo while preserving graft- ... Read More

2020年5月14日 — Jagasia et al convincingly demonstrate that ruxolitinib may rescue approximately half of patients with steroid-refractory acute GVHD: 1-year NRM ... Read More

由 R Zeiser 著作 · 2020 · 被引用 123 次 — Background: Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a ... Read More

由 M Jagasia 著作 · 2020 · 被引用 66 次 — Ruxolitinib produced durable responses and encouraging survival compared with historical data in patients with steroid-refractory aGVHD who ... Read More

由 B Modi 著作 · 2019 · 被引用 37 次 — Ruxolitinib, a selective JAK1/2 inhibitor, has recently gained favor as a second-line approach in patients with steroid-refractory cGVHD. ... Furthermore, we ... Read More

由 H Wu 著作 · 2021 · 被引用 3 次 — Thereafter, the Ruxolitinib for the Treatment of Steroid-Refractory Acute GVHD (REACH-1) study investigated ruxolitinib in treating SR-aGVHD and ... Read More

2020年5月29日 — Ruxolitinib, a targeted therapy that patients take as a pill, inhibits two proteins, JAK1 and JAK2, that are thought to play a role in GVHD. Read More

2021年2月23日 — In the overall trial, 48% of patients had moderate chronic GVHD and 52% had severe chronic GVHD. As of May 8, 2020, 50% of the patients had ... Read More

由 VE Gómez 著作 · 2020 · 被引用 24 次 — In summary, ruxolitinib in the real life setting has been shown as an effective and safe treatment option for GVHD patients, with an ORR of 69.5 ... Read More

2020年11月11日 — These documents set out the recommendations for the use of ruxolitinib in graft versus host disease (GvHD) in the context of COVID-19. Read More